RxDoctor Payments Data

Catherine Pechon, MD

Family Medicine · Madisonville, LANPI 1598177974

Payments from drug & device makers

$1,859in general payments, 2019–2025

Across 111 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$294
  • AstraZeneca$262
  • Boehringer Ingelheim$190
  • Sanofi-aventis U.S. LLC$124
  • Pfizer$102
  • GSK$99
  • plus $787 from 18 others

What the payments were for

  • Food & beverage$1,853100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,859 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$45,462
Medicare patients
164
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide47$63,090
EliquisApixaban60$57,151
OzempicSemaglutide22$52,936
JardianceEmpagliflozin37$43,265
JanuviaSitagliptin Phosphate36$33,321
MounjaroTirzepatide11$31,612
XareltoRivaroxaban24$19,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$19,344
LinzessLinaclotide16$18,977
VascepaIcosapent Ethyl17$6,239
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$4,204
SymbicortBudesonide/Formoterol Fumarate17$3,692
SynthroidLevothyroxine Sodium42$2,945
Arnuity ElliptaFluticasone Furoate11$2,890
Levothyroxine Sodium319$2,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$85$94,70258 claims
PfizerEliquis$102$57,15160 claims
Novo NordiskOzempic$294$52,93622 claims
Boehringer IngelheimJardiance$190$43,26537 claims
MerckJanuvia$67$33,32136 claims
GSKTrelegy Ellipta, Arnuity Ellipta$99$22,23337 claims
AbbVieLinzess, Synthroid$27$21,92258 claims
Johnson & JohnsonXarelto$99$19,94124 claims
AstraZenecaSymbicort$262$3,69217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Madisonville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →